Q&A

General

Could you please give our viewers a brief history of your company.

Modified

26.Oct 18

In brief, SCO-101 was originally developed by the Danish biotech company Neurosearch A/S to treat patients with Sickle Cell Anemia, which is a non-cancer hemoglobin disease. However, they were not satisfied with their first results and further development was stopped.

Neurosearch A/S was acquired by Saniona AB, which is on First North in Stockholm. At that time Nils Brünner, CEO of Scandion Oncology was CEO for WntResearch and the CFO in WntResearch, Thomas Feldthus, was one of the founders of Saniona. He introduced Nils Brünner to the CEO of Saniona, Jørgen Drejer, and several conversations about drug development were initiated. At the same time, Nils Brünner together with Associate Professor Jan Stenvang, at the University of Copenhagen, established a novel drug screening platform consisting of pairs of drug sensitive and drug resistant cancer cell lines. Nils Brünner and CSO Jan Stenvang obtained SCO-101 from Saniona and tested it in the screenings platform. The studies showed that SCO-101 by itself has no anti-cancer effects but when combined with standard cancer treatments in drug resistant cancer cell lines, SCO-101 blocked important resistance mechanisms rendering the cancer cells sensitive to treatment again. SCO-101 had been tested in 92 humans already at the time of Neurosearch and is now ready for phase II in cancer. We established Scandion Oncology in May 2017 and money is currently being raised to continue the clinical development in patients with drug resistant cancer.

Could you please share with us your favorite memory and or event since you joined the company?

Modified

26.Oct 18

The day we decided to spin-out Scandion Oncology from University of Copenhagen and Saniona. It was a dream that came through for us – to establish our own company based on our own cancer research. Only by taking SCO-101 through a commercialization process, we will be able to bring our many years of research out to the benefit of cancer patients.

During your time at Scandion Oncology what has been in your eyes your greatest achievement thus far?

Modified

26.Oct 18

To discover that SCO-101 could reverse drug resistance in cancer and to identify the mechanisms of actions for this effect.

What sets your company apart from those within your industry?

Modified

26.Oct 18

As far as we are aware, we are the only company having a drug against drug resistance in cancer in clinical development. So our “X factor” is a unique and safe oral drug that targets the perhaps most important problem in today’s cancer treatment: Existing or acquired drug resistance leading to the death of millions every year.

You are currently a very small organization, do you see any risk of overreaching by aiming to develop at least 3 different drugs concomitantly?

Modified

30.Dec 18

This is a very good comment. We are certainly aware of such a “positive” problem and we therefore have the clinical development of SCO-101 as our main focus. This also appears from our budget presented in the memorandum published in connection with the IPO. For the two other compounds, further development is related to securing economical support for these.

Immunotherapy has become a growing part of cancer treatment. How well will the old chemotherapies, which SCO-101 and SCO-201 hopefully will enhance, compete with new immunotherapies?

Modified

30.Dec 18

This is a very interesting and timely question. Roche, the big pharma company, has recently published that their check point inhibitors (immuno-oncology) works better if it is combined with chemotherapy. They showed this by combining their check point inhibitor with the chemotherapeutic drug Abraxane. Abraxane is paclitaxel bound to albumin. SCO-101 enhances the effects of paclitaxel and reverses paclitaxel resistance. Since quite a few of these patients will have paclitaxel resistant cancer cells, SCO-101 should be part of this combination to ensure cancer cell kill in the tumor thereby recruiting the immune cells. Thus, SCO-101 could be a very important addition to current immuno-oncology treatment.

There is a general notion that cancer stem cells are more resistant to chemotherapy than normal cancer cells. Do you have any indication that SCO-101 and/or SCO-201 will work on cancer stem cells?

Modified

30.Dec 18

Cancer stem cells are characterized by surviving cancer treatment and hence be responsible for recurrence of the cancer. Cancer stem cells have high expression of the ABCG2 drug efflux pump and they most probably use this pump to avoid the effects of chemotherapy. The ABCG2 drug efflux pump is being inhibited by SCO-101. Thus, we expect to kill cancer stem cells by combining chemotherapy with SCO-101. We have yet not looked at this but it is definitely in our development plans for 2019.

Is it the P-gp and BCRP drug efflux pumps that you are trying to block?

Modified

15.Jan 19

Yes, these efflux pumps are considered as the most important in anti-cancer drug resistance.

Could SCO-101 affect the toxin pumps in healthy cells, or does it only affect cancer cells?

Modified

15.Jan 19

Yes it is likely that the toxin pumps (which are also the P-gp and BCRP pumps) in healthy cells are effected as well . We circumvent this problem by introducing a SCO-101 treatment pause between chemotherapy treatment. There have been toxicity studies of SCO-101 (clinical phase I) showing that SCO-101 is well tolerated for prolonged use (14 days) at the dose that we intend to use as our starting dose.

When we combine SCO-101 with chemotherapy we do not expect additional  toxicity based on the published Tariquidar clinical data. Please see this recent review with relevant references (Robey et al., Nature Reviews Cancer (vol. 18, p.452–464 (2018)).

Pre-clinical

In one of your slides that you use for presentations, it says that you have identified a non-cancer indication for SCO-101. Can you tell us more about this other indication?

Modified

26.Oct 18

It is correct that we now have preclinical data on SCO-101 and a non-cancer indication. We are presently preparing for a new patent application for this. The only information I can give right now is that this other indication could be as big as the cancer indication. We will initiate screening of our approximately 800 SCO-101 analogs in order to select a candidate for this indication.

Clinical

When do you expect that breast cancer patients can receive your drug?

Modified

26.Oct 18

We plan to initiate in late 2019 the clinical phase II study with metastatic breast cancer patients and docetaxel/paclitaxel resistant disease. Please contact Nils Brünner CEO (nb@scandiononcology.com) for further information.

Do you have any plans to initiate clinical studies with SCO-101 in other indications than breast cancer?

Modified

26.Oct 18

Yes, we plan to initiate clinical studies also in colorectal cancer and most probably also in pancreatic cancer but we will need more resources in order to do this.

Jag undrar lite om era fas 1 studier, då jag inte hittar så mycket information om dessa. Hur kommer det sig att det gjorts hela fyra fas 1 studier? Då man oftast vill söka effekt i fas 2.

Modified

13.Nov 18

When Scandion Oncology was established in 2017 we received all documentation on the four Phase I clinical trials from Saniona. These trials were conducted around 2002 and the data were not published. We plan to include some of these data in our coming publications. All studies were performed in healthy volunteers. The four studies comprised

  1. Single doses
  2. Escalation doses
  3. Females and males
  4. Food interaction (since SCO-101 is delivered in a capsule)

The original plans for SCO-101 were to use it to treat a disease named sickle cell anemia. This is an inherited blood disease where the erythrocytes (red blood cells) have a sickle shape and they are more fragile. However, SCO-101 caused a slight and reversible increase in serum bilirubin and was therefore found unsuitable for treatment of a disease that results in increased serum bilirubin by itself.

This I fortunately not considered a problem when combining with anti-cancer treatment.

Has Scandion Oncology plans to collaborate with 2CureX or Oncology Venture in order to select the most relevant patients for the future clinical studies?

Modified

17.Dec 18

Scandion Oncology is currently investigating several possibilities to apply predictive biomarkers in order to personalize the treatment with SCO-101. These predictive biomarkers will eventually be used to select the patients who are most likely to respond to treatment with SCO-101.

A product called Tariquidar that inhibits drug efflux pumps was abandoned in phase III: Was this due to toxicology issues?

Modified

15.Jan 19

Yes, indeed Tariquidar was abandoned in Phase III clinical trials. We are well aware of these clinical studies. Based on the published literature on these clinical trial with Tariquidar it seems that there is not very much added toxicity when combining Tariquidar with chemotherapy (the phase I and II trials). However, it was observed that there were responders in patients with a favorable biomarker profile. Unfortunately, it is not totally clear how they selected patients for their trials. It seems unclear why they decided to terminate future development of Tariquidar and there seems not to be any publications describing unacceptable toxicities. We are of course looking closely into the Tariquidar papers when we plan our clinical studies. More information and references can be found in this review: Robey et al., Nature Reviews Cancer (vol. 18, p.452–464 (2018)

Financials

Is it correct that we can now pre-invest in Scandion Oncology?

Modified

26.Oct 18

We have just finalized the presubscription period, which went extremely well. From October 4, it will be possible to subscribe to Scandion Oncology shares at Spotlight. Please contact Nils Brünner, CEO (NB@ScandionOncology.com) for further information.

When does Scandion Oncology plan to have investor meetings in 2018?

Modified

26.Oct 18

There will be investor meetings at

Investerarträff Copenhagen, October 4, 2018

From 17:30-19:30

Radisson Royal Copenhagen,
Hammerichsgade 1,
1611 København V

Sedermeradagen Göteborg, October 11, 2018

From 11:00-18:00

Elite Park Avenue Hotel,
Kungsportsavenyen 36,
411 36 Göteborg

Investerarträff Stockholm, October 12, 2018

From 11:30-13:00

Scandic Klara,
Slöjdgatan 7,
111 57 Stockholm

How many staff do you have currently on the team

Modified

26.Oct 18

We have a CEO (Nils Brünner), a CSO (Jan Stenvang), a CMO (Peter Michael Vestlev) and a CFO (Carit Andersen).

Do any of the staff and or management team hold any shares within the company?

Modified

26.Oct 18

We all do and we have all invested in the Scandion Oncology.

What are Scandion Oncology´s medium to long-term goals and have these goals been consistent for some time?

Modified

26.Oct 18

To successfully pass clinical phase II with SCO-101, thereby obtaining clinical proof-of-concept, and then find a partner or a licensee. Next step will be to take our second drug candidate, SCO-201 through preclinical and clinical development.

Presentation

Media element